Interpretation of results

For androgen replacement therapy and male hormonal contraception there is a need for orally active androgens which can substitute the total spectrum of physiological effects of testosterone, preferably at a lower dose. In the search for new orally active androgens, a combination of in vitro and in vivo assays has been used with the aim to select androgens with higher androgen receptor affinity and less metabolic instability than the reference androgen, testosterone. Additional prerequisites of new androgens are some aromatization towards estrogenic metabolites and the absence of androgen receptor activation upon 5a-reduction (like testosterone) to obtain a prostate-sparing effect.

We exploited the fact that nandrolone and 7a-methyl nandrolone (MENT) have 3- and 10-fold increased androgen receptor binding affinity as compared to testosterone, respectively (Bergink etal. 1985; Kumar etal. 1999). However, these andro-gens have not been developed further for oral application due to their limited oral efficacy. The oral efficacy of MENT was expected since both high androgen receptor activity and high metabolic stability have been reported using rat liver microsomes (Agarwal and Monder 1988). Our metabolic stability assay, using intact human hep-atocytes, indicates that there is no difference in the metabolism between nandrolone, MENT and the metabolically unstable reference androgen, testosterone. A plausible explanation for this difference is that the cofactor (NAD) for the most important androgen inactivating enzyme, the microsomal enzyme 17^-hydroxysteroid dehydrogenase type 2, is not added to the microsomal preparation (Puranen etal. 1999). In addition, the low metabolic stability of MENT is also more in line with the pharmacokinetic data in different species and the relative low oral efficacy of MENT in the LH-suppression test using castrated male rats. Our hypothesis was that 7a-alkyl elongation/unsaturation of nandrolone would improve metabolic stability while maintaining androgen receptor affinity. Indeed, 7a-ethylnandrolone is a metabolically relative stable androgen having a good androgen receptor binding affinity. This androgen resulted in good LH suppression in the rat, 4-fold more potent than MENT. Since the pharmacokinetic data in rat, rabbit and monkey indicated low exposure after oral application, this compound was not evaluated further.

Of all nandrolone derivatives tested, OrgXis the most metabolically stable androgen. The excellent in vitro data of OrgX (high receptor activity and metabolic stability) was confirmed by several in vivo tests. After a single oral dose of Org X pharmacokinetic evaluation revealed that both in the rabbit and monkey good kinetics were found. In general, the more or less similar pharmacokinetic behaviour of steroids after oral application in the rabbit and monkey differs from that in the rat. Efficacy studies also indicated that OrgX is a potent oral androgen. In the LH-suppression test using male castrated rats, the oral activity of Org X is 0.3 mg/kg, which is 200, 100 and 45-fold better than the oral efficacy of testosterone, testosterone-undecanoate and MENT, respectively. In the rat osteoporosis test, Org X is around 40-fold more active than testosterone in maintaining trabecular BMD at intact levels. A similar increase in efficacy of Org X for LH/FSH suppression was observed. At this BMD/LH/FSH replacement dose of Org X a clear prostate-sparing effect was observed. The high potency of Org X was confirmed in intact male monkeys. A once-daily dose of only 8 |xg/kg was needed for 60% suppression of endogenous testosterone. Even at this low dose, trough levels (24 hours after application) of 1.8 nmol/l of Org X were found. The relatively low efficacy of 17a-methyltestosterone in the rat LH suppression test was confirmed by the relative high dose (666 |xg/kg) required for testosterone suppression in the male monkey (Ubink et al. 2003). On the basis of ventral prostate weight stimulation in rats, a 50-fold higher potency of 17a-methyltestosterone compared with testosterone was expected (Segaloff 1963). These data indicate that LH suppression in rats is far more indicative of the required profile of a new androgen than ventral prostate stimulation.

22.6 Key messages

• 7a-alkylation of nandrolone increases the AR agonistic activity.

• Org X is a novel 7a-alkylated nandrolone derivative.

• 7a-ethylnandrolone and Org X are metabolically stable compounds as determined after incubation with human hepatocytes.

• 7a-substituted nandrolone derivatives and Org X can be converted in vitro by recombinant human aromatase to active estrogens, just like the natural androgen testosterone.

• Org X is around 40 times more potent than testosterone undecanoate in the castrated male rat in maintaining trabecular mineral bone density, LH and FSH suppression and anabolic effects. At the bone-protecting dose, a prostate-sparing effect of Org X was observed.

• With a once daily oral dose for seven days of 8 ^g/kg of Org X suppression of endogenous plasma testosterone in intact male monkeys was observed.

• Pharmacokinetic data obtained after one single oral dose revealed no differences in the rat between the different nandrolone derivatives.

• Pharmacokinetic parameters after single oral application of the different nandrolone derivatives and reference compounds revealed that the rabbit is more predictive for the monkey than the rat.

• LH suppression in the rat is more indicative of the required profile of a new androgen than ventral prostate stimulation.


AgarwalAK, MonderC (1988) In vitro metabolism of 7 alpha-methyl-19-nortestosterone by rat liver, prostate, and epididymis. Endocrinology 123:2187-2193

Anonymous(1962) 7-methyltestosterone and derivatives (BE 610385), 1-25 16-5-1962 (Patent)

Bergink EW, Janssen PS, Turpijn EW, van der Vies J (1985) Comparison of the receptor binding properties of nandrolone and testosterone under in vitro and in vivo conditions. J Steroid Biochem 22:831-836

Bergink EW, van Meel F, Turpijn EW (1983) Binding of progestagens to receptor proteins in

MCF-7 cells. J Steroid Biochem 19:1563-1570 Bursi R, de Gooyer ME, Grootenhuis AJ, Jacobs PL, van der LJ, Leysen D (2001) (Q) SAR study on the metabolic stability of steroidal androgens. J Mol Graph Model 19:552-558 Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ (1998) Prostate-sparing effects in primates of the potent androgen 7alpha- methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 83:4212-4219

de Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HA, Kloosterboer HJ (2003) Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): Analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 68:235-243

Ederveen AG, Kloosterboer HJ (2001) Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 16:1651-1657 Herschberger LG, Shipley EV, Meyer RK (1953) Myotrophic activity of 19-Nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exper Biol Med 83:175-180

Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS (1996) Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action ofthese hormones. Mol Endocrinol 10:119-131 Kirk-Otmar (1983) Steroids. In: Encyclopedia of chemical technology Silver and silver alloys to sulfolanes and sulfones (Kirk-Otmar), John Wiley & Sons pp 645-728 Kumar N, Crozat A, Li F, Catterall JF, Bardin CW, Sundaram K (1999) 7alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: structure-activity comparisons with other androgens. J Steroid Biochem Mol Biol 71:213-222 Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K (1992) The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 130:3677-3683 Kunzer H, Sauer G, Wiechert R Tetrahedron (2003) (Letter) 32:743

Puranen TJ, Kurkela RM, Lakkakorpi JT, Poutanen MH, Itaranta PV, Melis JP, Ghosh D, Vihko RK, Vihko PT (1999) Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Endocrinology 140:33343341

Schoonen WG, de Ries RJ, Joosten JW, Mathijssen-Mommers GJ, Kloosterboer HJ (1998) Development of a high-throughput in vitro bioassay to assess potencies of progestagenic compounds using Chinese hamster ovary cells stably transfected with the human progesterone receptor and a luciferase reporter system. Analyt Biochem 261:222-224

Segaloff A (1963) The enhanced local androgenic activity of 19-nor steroids and stabilization of their structure by 7alpha- and 17alpha-methyl substituents to highly potent androgens by any route of administration. Steroids 1:299-315 Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M (2002)

Aromatase-a brief overview. Annu Rev Physiol 64:93-127 Ubink R, Kop W, Grootenhuis AJ (2003) Suppression of endogenous testosterone with a new orally active androgen in male Maccaca arctoides. (in preparation) van Casteren JI, Schoonen WG, Kloosterboer HJ (2000) Development of time-resolved immunofluorometric assays for rat follicle-stimulating hormone and luteinizing hormone and application on sera of cycling rats. Biol Reprod 62:886-894 van der Louw J, Leysen D, Buma-BursiH (2003) Orally active androgens (WO 00/59920) (Patent) Vida JA (1969) Androgens and anabolic agents. Academic Press, New York, London, pp 1-327 Zeelen FJ (1990) Steroid synthesis. In: FJ Zeelen, Medicinal chemistry of steroids, Elsevier, Amsterdam, pp 315-325

Hair Loss Prevention

Hair Loss Prevention

The best start to preventing hair loss is understanding the basics of hair what it is, how it grows, what system malfunctions can cause it to stop growing. And this ebook will cover the bases for you. Note that the contents here are not presented from a medical practitioner, and that any and all dietary and medical planning should be made under the guidance of your own medical and health practitioners. This content only presents overviews of hair loss prevention research for educational purposes and does not replace medical advice from a professional physician.

Get My Free Ebook

Post a comment